Procedures of data merging in precision cancer medicine: the PRIME-ROSE project
Data sharing across European trials is feasible and enhances the advancements of PCM studies. The methodologies developed in the PRIME-ROSE project provide a foundation for future data integration efforts in PCM clinical trials, underscoring the viability of conducting robust trials in a global context.
Authors
- Soemeya Haj Mohammad
- Marta Fiocco (ORCID: https://orcid.org/0000-0001-5588-0277)
- Maria Martin Agudo (ORCID: https://orcid.org/0000-0003-3605-9963)
- Henk van der Pol
- Kristoffer Staal Rohrberg (ORCID: https://orcid.org/0000-0002-5448-9003)
- U. Lassen
- Kristiina Ojamaa (ORCID: https://orcid.org/0000-0003-1990-5670)
- RS Falk
- Sarah Halford (ORCID: https://orcid.org/0000-0002-8110-9766)
- Victoria Homer (ORCID: https://orcid.org/0000-0003-3639-7874)
- E. Baltruškevičienė
- Hans Timmer (ORCID: https://orcid.org/0009-0002-3822-7326)
- T.M. Kringelbach
- K. Tasken
- Loïc Verlingue (ORCID: https://orcid.org/0000-0002-5694-4022)
- Matthew Krebs (ORCID: https://orcid.org/0000-0001-7540-3064)
- Gro Live Fagereng (ORCID: https://orcid.org/0000-0003-2600-6606)
- Åslaug Helland
- G. Bratseth Stav
- T Juslin
- Júlio Oliveira
- Katriina Jalkanen
- Hans Gelderblom
Institutions
- Leiden University (NL)
- Oslo University Hospital (NO)
- Leiden University Medical Center (NL)
- Helsinki University Hospital (FI)
- Tartu University Hospital (EE)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- University of Manchester (GB)
- Instituto Português de Oncologia Francisco Gentil (PT)
- Centre Léon Bérard (FR)
- Cancer Research Horizons (GB)
- Cancer Registry of Norway (NO)
- The Christie NHS Foundation Trust (GB)
- Cancer Research UK Clinical Trials Unit (GB)
- National Cancer Institute (LT)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2026-01-06
- DOI
- https://doi.org/10.2340/1651-226x.2026.44889
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 49.63
Funders
- Pfizer
- Sanofi
- National Institute for Health and Care Research
- Universitetet i Oslo
- Genentech
- Manchester Biomedical Research Centre
- HORIZON EUROPE Framework Programme
- Cilag